Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys

Food and Chemical Toxicology

Volumn 52, Issue , 2013, Pages 143-152

  Tian, Jingwei ^a   Du, Guangying ^a   Ye, Liang ^a   Yu, Xin ^a   Zhang, Jianzhao ^a   Wang, Hongbo ^a   Yu, Pengfei ^a   Fu, Fenghua ^a   Liu, Wanhui ^a   Li, Youxin ^a   Cen, Xiaobo ^b   Guan, Xiaolin ^b  

^a YANTAI UNIVERSITY   (China)

^b WestChina Frontier PharmaTech/GLP Center   (China)

Author keywords

Continuous dopaminergic stimulation; Dopamine agonist; Parkinson's disease; Rotigotine loaded microspheres; Subchronic toxicity; Sustained release

Indexed keywords

CARBOXYMETHYLCELLULOSE; MICROSPHERE; POLYGLACTIN; PROLACTIN; ROTIGOTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; BRAIN DEGENERATION; BREATHING RATE; CLINICAL CHEMISTRY; CONTROLLED STUDY; CYNOMOLGUS; CYTOLOGY; ELECTROCARDIOGRAPHY; FEMALE; FOAM CELL; GRANULOMA; HAPLORHINI; HISTOPATHOLOGY; HYPERACTIVITY; LUNG EMBOLISM; MALE; MONONUCLEAR CELL; MORTALITY; NEUTROPHIL COUNT; NONHUMAN; OPHTHALMOSCOPY; ORGAN WEIGHT; PROLACTIN BLOOD LEVEL; THYMUS ATROPHY; TOXICITY TESTING; TOXICOKINETICS; URINALYSIS;

ANIMALS; ATROPHY; BLOOD PRESSURE; BODY TEMPERATURE; BODY WEIGHT; BONE MARROW; DOPAMINE AGONISTS; EATING; ELECTROCARDIOGRAPHY; FEMALE; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS; MALE; MICROSPHERES; MORTALITY; ORGAN SIZE; PARKINSON DISEASE; POLYGLACTIN 910; PROLACTIN; PULMONARY EMBOLISM; TETRAHYDRONAPHTHALENES; THIOPHENES; THYMUS GLAND; TOXICITY TESTS, SUBCHRONIC;

EID: 84875098767     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.11.010     Document Type: Article

References (28)

1. Antonini A., Ursino G., Calandrella D., Bernardi L., Plebani M. Continuous dopaminergic delivery in Parkinson's disease. J. Neurol. 2010, 257:S305-S308.
2. Aviles-Olmos I., Martinez-Fernandez R., Foltynie T. L-DOPA-induced dyskinesias in Parkinson's disease. Eur. Neurol. J. 2010, 2:91-100.
3. Baldwin C.M., Keating G.M. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. CNS Drugs 2007, 21:1039-1055.
4. Ben-Jonathan N., Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 2001, 22:724-763.
5. Blandini F., Armentero M.T. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. Expert Opin. Investig. Drugs 2012, 21:153-168.
6. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010, 9:1106-1117.
7. Chen J.J., Swope D.M., Dashtipour K., Lyons K.E. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy 2009, 29:1452-1467.
8. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
9. Dorati R., Genta I., Colonna C., Modena T., Pavanetto F., Perugini P., Conti B. Investigation of the degradation behaviour of poly(ethylene glycol-co-d,l-lactide) copolymer. Polym. Degrad. Stab. 2007, 92:1660-1668.
10. Freiberg S., Zhu X.X. Polymer microspheres for controlled drug release. Int. J. Pharm. 2004, 282:1-18.
11. Gottwald M.D., Aminoff M.J. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann. Neurol. 2011, 69:919-927.
12. Malik M., Andreas J.O., Hnatkova K., Hoeckendorff J., Cawello W., Middle M., Horstmann R., Braun M. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin. Pharmacol. Ther. 2008, 84:595-603.
13. Mutch W.J., Dingwall-Fordyce I., Downie A.W., Paterson J.G., Roy S.K. Parkinson's disease in a Scottish city. Br. Med. J. (Clin. Res. Ed.) 1986, 292:534-536.
14. Odin P., Wolters E., Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol. Sci. 2008, 29(Suppl 5):S387-S388.
15. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-687.
16. Rascol O., Lozano A., Stern M., Poewe W. Milestones in Parkinson's disease therapeutics. Mov. Disord. 2011, 26:1072-1082.
17. Reichmann H. Transdermal delivery of dopamine receptor agonists. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S93-S96.
18. Rose S., Scheller D.K., Breidenbach A., Smith L., Jackson M., Stockwell K., Jenner P. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav. Pharmacol. 2007, 18:155-160.
19. Samanta J., Hauser R.A. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin. Pharmacother. 2007, 8:657-664.
20. Sanford M., Scott L.J. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. CNS Drugs 2011, 25:699-719.
21. Schmidt W.J., Lebsanft H., Heindl M., Gerlach M., Gruenblatt E., Riederer P., Mayerhofer A., Scheller D.K. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J. Neural. Transm. 2008, 115:1385-1392.
22. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28:5-24.
23. Sprenger F.S., Seppi K., Poewe W. Drug safety evaluation of rotigotine. Expert. Opin. Drug Saf. 2012, 11:503-512.
24. Stocchi F. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J. Neurol. 2011, 258:S316-S322.
25. Stockwell K.A., Scheller D.K., Smith L.A., Rose S., Iravani M.M., Jackson M.J., Jenner P. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. Exp. Neurol. 2010, 221:79-85.
26. Sujith O.K., Lane C. Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease. Ther. Adv. Neurol. Disord. 2009, 2:105-113.
27. Van der Weide J., Tendijck M.E., Tepper P.G., De Vries J.B., Dubocovich M.L., Horn A.S. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur. J. Pharmacol. 1988, 146:319-326.
28. Wang A., Wang L., Sun K., Liu W., Sha C., Li Y. Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats. Pharm. Res. 2012, 29:2367-2376.